Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

• Published in: The New England journal of medicine Vol. 380; no. 1; pp. 45 - 56
• Main Authors: Schuster, Stephen J, Bishop, Michael R, Tam, Constantine S, Waller, Edmund K, Borchmann, Peter, McGuirk, Joseph P, Jäger, Ulrich, Jaglowski, Samantha, Andreadis, Charalambos, Westin, Jason R, Fleury, Isabelle, Bachanova, Veronika, Foley, S. Ronan, Ho, P. Joy, Mielke, Stephan, Magenau, John M, Holte, Harald, Pantano, Serafino, Pacaud, Lida B, Awasthi, Rakesh, Chu, Jufen, Anak, Özlem, Salles, Gilles, Maziarz, Richard T
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 03.01.2019
• Subjects: Adult; Adults; Aged; Autografts; B-cell lymphoma; Biomarkers; Biopsy; Cancer och onkologi; CD19 antigen; Chemotherapy; Chimeric antigen receptors; Clinical trials; Cytokines; Edema; Editorials; Evidence-based medicine; Farmakologi och toxikologi; FDA approval; Female; Humans; Immune checkpoint; Immunotherapy; Immunotherapy, Adoptive; Klinisk medicin; Lymphocytes B; Lymphocytes T; Lymphoma; Lymphoma, Large B-Cell, Diffuse - mortality; Lymphoma, Large B-Cell, Diffuse - pathology; Lymphoma, Large B-Cell, Diffuse - therapy; Male; Medical prognosis; Medicin och hälsovetenskap; Medicinska och farmaceutiska grundvetenskaper; Middle Aged; Neoplasm Grading; Neutropenia; Progression-Free Survival; Receptors, Antigen, T-Cell - therapeutic use; Receptors, Chimeric Antigen - therapeutic use; Recurrence; Stem cell transplantation; Survival Analysis; Transplants & implants; Young Adult; United States > US
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa1804980

The capacity to use CAR T-cell therapy has been limited by the need to produce cells in a specialized laboratory. In this study, 40% of patients with relapsed or refractory diffuse large B-cell lymphoma may have had durable complete responses with cells manufactured in a central commercial laboratory.